What You Should Know:
– BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions and bioMérieux, a world leader in the field of in vitro diagnostics, announced today a partnership to develop and bring to market a Clinical Digital Solution for diagnostics enabling clinical decision support for disease areas across their diagnostic tests.
– bioMérieux will launch a digital solution for diagnostics leveraging the compliant BrightInsight® Platform and BrightInsight Disease Management Solution; technology that can be configured to meet the highest regulated digital health Software as a Medical Device (SaMD) classifications.
Expanding Horizons in Clinical Diagnostics Using Data-Driven Solutions
As healthcare providers are increasingly charged with delivering better patient outcomes at a lower total cost of care, it is critical that clinicians leverage the insights delivered by high-value diagnostics in a timely, optimal manner. To address this healthcare need, bioMérieux will launch a digital solution for diagnostics leveraging the compliant BrightInsight® Platform and BrightInsight Disease Management Solution. This solution will improve clinical workflows, contextualize disease awareness, and ultimately enable a more holistic patient view to support clinicians in making actionable, informed decisions. bioMérieux’s Clinical Digital Solution will launch first in the US, with planned global expansion.
“We are honored to partner with bioMérieux to support the development of their Clinical Digital Solution for diagnostics that include clinical decision support tools used in the ICU, to assess risk and help reduce incidence of preventable diseases,” said Kal Patel, M.D., CEO & Co-Founder, BrightInsight. “bioMérieux is a recognized in vitro diagnostics leader, joining a stellar group of life science companies leveraging our proven, compliant BrightInsight Platform as the foundation for their transformational SaMD and digital health solutions.”
